Cargando…
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with CD33(+) acute myelo...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943952/ https://www.ncbi.nlm.nih.gov/pubmed/36845850 http://dx.doi.org/10.1177/20406207231154708 |